Erythropoietin-stimulating protein NESP

More recently, novel erythropoiesis-stimulating-protein (Nesp) or darbapoetin alfa (Aranesp) has been approved for clinical use in patients with indications similar to those for epoetin alfa. It is a genetically modified form of erythropoietin in which four amino acids have been mutated such that additional carbohydrate side chains are added during its synthesis, prolonging the circulatory survival of the drug to 24 to 26 hours. 

Abbreviations rhuEPO, recombinant human erythropoietin NESP, novel erythropoiesis stimulating protein derived from genetic modification of rhuEPO to create two additional N-linked gylcosylation sites. 

---